Answers are grounded in this paper and cite their sources.
Use of SGLT2is or GLP-1RAs compared with sulfonylureas was associated with a lower risk of hypoglycemia among patients with CKD and type 2 diabetes. Black race was not only associated with lower use of newer agents with demonstrated cardiovascular and kidney benefits and lower hypoglycemia risk, but also with a higher rate of hypoglycemic events as compared with White individuals.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: